United Therapeutics Corporation (UTHR) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Silver Spring, MD, United States. Le PDG actuel est Martine A. Rothblatt.
UTHR a date d'introduction en bourse 1999-06-17, 1,305 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $25.36B.
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with chronic and life-threatening diseases, particularly pulmonary hypertension and related conditions. The company's commercial portfolio includes Remodulin, Tyvaso, Orenitram, and Adcirca for treating pulmonary arterial hypertension, as well as Unituxin for high-risk neuroblastoma. United Therapeutics maintains an active pipeline of innovative treatments including gene therapies, advanced drug delivery systems, and next-generation formulations, supported by strategic partnerships with leading medical device and pharmaceutical companies. Headquartered in Silver Spring, Maryland, the company operates globally to address significant unmet medical needs in pulmonary hypertension and oncology.
